Mercury Laboratories Limited

Mercury Laboratories Limited, established in 1962, is a prominent Indian pharmaceutical company headquartered in Vadodara, Gujarat. The company specializes in the manufacturing, marketing, and export of a diverse range of pharmaceutical formulations, with a strong emphasis on mother and child healthcare. Its product portfolio includes tablets, oral liquids, injections, small volume parenterals, and ophthalmic preparations.

Incorporated as a public limited company on February 12, 1982, under the Corporate Identification Number (CIN) L74239MH1982PLC026341, Mercury Laboratories Limited has demonstrated consistent growth and innovation in the pharmaceutical sector. The company is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 538964. As of March 11, 2026, the stock price was ₹780.00, reflecting a 1.04% increase from the previous close.

Mercury Laboratories Limited operates with an authorized capital of ₹25 million and a paid-up capital of ₹12 million. The company employs approximately 503 individuals, underscoring its significant presence in the pharmaceutical manufacturing industry. For more information, visit their official website at www.mercurylabs.com.

Mercury Laboratories Limited boasts a state-of-the-art manufacturing facility spanning 435,600 square feet (approximately 40,468 square meters) in Vadodara, Gujarat. This expansive facility is equipped with modern technology to produce pharmaceutical products that meet international standards and specifications. The manufacturing units are designed to operate in various dosage forms and accommodate a wide range of batch sizes, ensuring flexibility and efficiency in production.

The leadership team at Mercury Laboratories Limited is headed by Chief Executive Officer (CEO) and Managing Director (MD) Rajendra Ramanlal Shah, who has been with the company since its inception. Other key executives include Non-Executive Non-Independent Director Dilip Ramanlal Shah, appointed on February 16, 1982, and Non-Executive Non-Independent Director Paresh Jagdishbhai Mistry, appointed on October 1, 2017. The board also includes Independent Chairperson Sanjay Shantilal Patel, appointed on May 14, 2025, and Non-Executive Independent Director Jayantilal Dhaneshwar Raval, appointed on July 24, 2024.

Mercury Laboratories Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports its pharmaceutical products to approximately 25 countries, including the United States and the United Kingdom. While specific regulatory filings and approvals in these markets are not detailed in the available sources, the company's export activities suggest compliance with international regulatory standards.

The company has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. Mercury Laboratories Limited exports its products to countries such as Ghana, Nigeria, Mozambique, Zambia, Kenya, Ivory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, and Ecuador. Additionally, the company has obtained approvals from regulatory bodies in these regions, including the Ghana FDA, DPML Ivory Coast, MoH R D Congo, CDDA Sri Lanka, and MoH Cambodia.

Mercury Laboratories Limited's geographic strategy demonstrates a balanced approach, with a significant focus on both developed and emerging markets. The company's export activities to approximately 25 countries indicate a diversified market presence, reducing reliance on any single region. This diversification strategy helps mitigate concentration risk and positions the company for sustained growth across various global markets.

Specific details regarding Mercury Laboratories Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's export activities to the United States suggest compliance with FDA regulations and standards. For comprehensive information, it is recommended to consult the FDA's official database or contact the company directly.

Mercury Laboratories Limited's manufacturing facilities are certified with WHO Good Manufacturing Practice (GMP) Unit-1 and Unit-2 certifications, indicating adherence to international quality standards. Additionally, the company has obtained WHO GMP Unit-2 certification, further demonstrating its commitment to quality manufacturing practices.

Mercury Laboratories Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has also obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities. These regulatory approvals underscore the company's compliance with Indian pharmaceutical manufacturing and export regulations.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Mercury Laboratories Limited. This absence suggests a favorable regulatory standing. For the most current information, it is advisable to consult the FDA's official database or contact the company directly.

Mercury Laboratories Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as gastrointestinal and advanced antibiotics. While specific market share comparisons are not detailed in the available sources, the company's export activities to approximately 25 countries indicate a robust market presence. A head-to-head analysis would require access to detailed market data and competitor performance metrics.

Mercury Laboratories Limited's commitment to mother and child healthcare distinguishes it in the pharmaceutical industry. The company's extensive product portfolio across multiple therapy segments, including gynecology, pediatrics, hemostasis, multi-vitamins, and pain management, reflects its dedication to addressing diverse healthcare needs. Additionally, the company's adherence to international quality standards, as evidenced by its WHO GMP certifications, enhances its competitive advantage.

Mercury Laboratories Limited's current strategic direction focuses on the development and marketing of generic pharmaceutical formulations, with a strong emphasis on mother and child healthcare. The company's expansion into emerging markets and adherence to international quality standards position it for sustained growth. Future outlooks may include diversification into specialty pharmaceuticals, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, contingent upon market dynamics and strategic objectives.

Mercury Laboratories Limited has a track record of consistent export volume and reliability, as evidenced by its export activities to approximately 25 countries. The company's adherence to international quality standards, including WHO GMP certifications, underscores its commitment to delivering high-quality pharmaceutical products. Reliability indicators such as on-time delivery and compliance with regulatory standards further enhance its reputation as a dependable supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's registration status with the FDA to ensure compliance with U.S. regulations.

• WHO GMP Certification: Verify the WHO GMP certifications to ensure adherence to international manufacturing standards.

• EU GMP Certification: Check for EU GMP certifications to confirm compliance with European manufacturing standards.

• ISO Certifications: Review ISO certifications, such as ISO 9001:2008, to assess the company's quality management systems.

Each certification can typically be verified through the issuing authority's official website or by contacting the company directly.

Importers should undertake the following verification steps:

• Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Quality Assurance: Review the company's quality management systems and certifications to ensure product quality.

• Financial Stability: Assess the company's financial health through audited financial statements and credit reports.

• Supply Chain Reliability: Evaluate the company's supply chain processes, including sourcing, manufacturing, and distribution capabilities.

Red flags